Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Prospective, Randomized, Open-label, Intra-subject Controlled Study of the Efficacy and Safety of ABH001 for the Treatment of Stalled Chronic Cutaneous Wounds Associated With Generalized Epidermolysis Bullosa

NCT01749306 is registered in ClinicalTrials.gov with Shire Regenerative Medicine, Inc. as lead sponsor.

NCT NCT01749306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01749306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Prospective, Randomized, Open-label, Intra-subject Controlled Study of the Efficacy and Safety of ABH001 for the Treatment of Stalled Chronic Cutaneous Wounds Associated With Generalized Epidermolysis Bullosa
Lead sponsor
Shire Regenerative Medicine, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
December 31, 2012
Completion date
November 30, 2013
Enrollment
1 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

epidermolysis bullosa